In the News
In the News
Advanced Oxygen Therapy Inc. Named Among the 10 Most Innovative MedTech Solution Providers to Watch in 2021
AOTI announced today that it had been named among the 10 Most Innovative MedTech Solution Providers to Watch in 2021 by the journal The Healthcare Insights and is highlighted as the cover story of its May 2021 print edition.
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds.
Maintain Continuity-of-Care During the COVID-19 Pandemic
HELPING MAINTAIN CONTINUITY-OF-CARE DURING THE COVID-19 PANDEMIC TWO2 MULTI-MODALITY TOPICAL WOUND OXYGEN THERAPY PROVIDES PROVEN HEALING & WOUND PROTECTIVE CARE SAFELY FOR YOUR PATIENTS AT HOME (1) (2) (3)(1) Diabetes Care 2020; 43:616-624 (2) Vascular and...
Topical Wound Oxygen (TWO2) therapy Treats High-Risk Patients Safely at Home during the COVID-19 Pandemic
AOTI Inc. announced today that since the outbreak of the COVID-19 pandemic it has been focusing all its resources on supporting a growing number of wound care patients being treated at home by its unique multi-modality Topical Wound Oxygen (TWO2) therapy.
AOTI Inc.’s state of the art RCT receives editorial commentary in Diabetes Care, March 2020.
Breakthrough RCT Published in Leading ADA Journal “Diabetes Care” Shows Multi-Modality Topical Wound Oxygen (TWO2) Therapy is Six-Times More Effective Healing & Reducing Recurrence of Diabetic Foot Ulcers
AOTI Inc. today announced that a state-of-the-art Randomized Controlled Trial (RCT) demonstrating the efficacy of its unique multi-modality cyclical pressure Topical Wound Oxygen (TWO2) therapy in healing and reducing recurrence of Diabetic Foot Ulcers (DFU) has been...
AOTI Inc. Awarded New Five-Year Federal Supply Schedule Contract by the Department of Veterans Affairs
OCEANSIDE, Calif., June 19, 2019 /PRNewswire/ -- AOTI Inc. today announced that it has been awarded a new five-year Federal Supply Schedule (FSS) contract for its patented Topical Wound Oxygen (TWO2) therapy by the National Acquisition Center, U.S....
AOTI’s Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading Worldwide Wound Care Conferences
It is clear there is a growing tsunami of interest in our products and their unprecedented complete healing benefits. We expect and hope that as our latest state-of-the-art Randomized Controlled Trial (RCT) is published that TWO2therapy will be made available to all chronic wound patients worldwide.
AOTI Enters Into Multi-Million USD Strategic Relationship for Chinese Market
OCEANSIDE, Calif., Jan. 18, 2019 /PRNewswire/ -- AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen (TWO2)...